In January 2018, Biogen dosed the first patient in the Phase 2 SPARK study of BIIB054 (anti-alpha-synuclein antibody) in Parkinson's disease.
The ZKB TECHNOPARK® Pioneer Award is given for technological innovations which – thanks to pioneering entrepreneurial achievements – are about to be launched on the market. The name «Pioneer Award» expresses the pioneering spirit of young entrepreneurs who develop a project to market maturity. The Award is endowed with CHF 98,696.04, a figure that represents 10,000 times ∏2 (pi squared). In 2010, at its 20th anniversary, Neurimmune received the award for its unique and promising avenue of research known as RTM™ (Reverse Translational Medicine) for their internationally unique research work in the development of drugs for the prevention and treatment of Alzheimer’s disease.